Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ABIO ARCA biopharma (ABIO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipShort InterestTrends About ARCA biopharma Stock (NASDAQ:ABIO) 30 days 90 days 365 days Advanced Chart Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get ARCA biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.40▼$599.0452-Week Range N/AVolume290,800 shsAverage Volume607,995 shsMarket Capitalization$34.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Read More… Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABIO Stock News Headlines18-Year-Old Sean Hingorani Makes It Back-to-Back ARCA West ChampionshipsNovember 9, 2024 | msn.comControversial ARCA Star Drops Heartbreaking Revelation as He Breaks Silence on Failing Career StabilityNovember 9, 2024 | msn.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 23, 2024 | WealthPress (Ad)Bitget Expands GameFi Offerings with Legend of Arcadia (ARCA) Listing and Airdrop EventsNovember 5, 2024 | markets.businessinsider.comCall The Pizza Man: Brayton Laster Set To Run Full ARCA Season with Wayne Peterson MotorsportsNovember 1, 2024 | msn.comNASCAR Weekend at Rockingham Speedway to Include ARCA Menards Series EastOctober 11, 2024 | msn.comFMR LLC Acquires New Stake in ARCA biopharma IncOctober 8, 2024 | finance.yahoo.comNASCAR’s ARCA division releases 2025 schedule, will air Daytona opener on FOXSeptember 28, 2024 | msn.comSee More Headlines ABIO Stock Analysis - Frequently Asked Questions How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) announced its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) earnings per share for the quarter, beating the consensus estimate of ($341.28) by $292.32. When did ARCA biopharma's stock split? ARCA biopharma shares reverse split on Tuesday, September 3rd 2024. The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Block (SQ), Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), Palantir Technologies (PLTR), ChargePoint (CHPT) and CrowdStrike (CRWD). Company Calendar Last Earnings8/04/2021Dividend Payable8/28/2024Ex-Dividend for 8/28 Dividend8/29/2024Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.18% Return on Assets-19.51% Debt Debt-to-Equity RatioN/A Current Ratio26.61 Quick Ratio26.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / BookN/AMiscellaneous Outstanding Shares14,507,000Free Float10,024,000Market Cap$34.82 million OptionableOptionable Beta0.91 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:ABIO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARCA biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
